Arthritis drug tested for Long-Term safety in kids
NCT ID NCT01673919
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at the long-term safety of the drug tocilizumab (Actemra) in 7 children with a type of arthritis called juvenile idiopathic arthritis. All children had already completed a previous study and continued to receive the drug every 4 weeks for up to 2 years. The main goal was to track any side effects or serious health issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (brand name Actemra/RoActemra)
What this could lead to
If successful, this could confirm that long-term use of tocilizumab is safe for managing juvenile idiopathic arthritis in children.
What could go wrong
This is a very small extension study (7 people) with no comparison group, so results may not apply broadly. Side effects like infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Le Kremlin-Bicêtre, 94275, France
-
Study site
Montpellier, 34295, France
-
Study site
Paris, 75679, France
-
Study site
Paris, 75743, France